Marijuana may be the biggest opportunity for investors these days, as shares of companies in the cannabis industry keep rallying. With the prospects of further legalization and changing public perceptions about marijuana, some investors will likely end up making millions of dollars over the next few years, while others will
Given the tremendous potential of the cannabis industry, it’s natural for investors to be attracted to marijuana stocks. Investors have stars in their eyes. My inbox is flooded with offers to make me a marijuana multimillionaire. Age-old “pump-and-dump” schemes are in full bloom in marijuana stocks. The headline of this
There was a big bombshell in marijuana land. Constellation Brands STZ, known for its beer, wine and spirits, is investing about $4 billion in Canadian marijuana company Canopy Growth CGC. Constellation paid a whopping 51% premium. So does that mean other marijuana stocks are worth about 50% more than they
This is an instructive tale of how some investors with the right knowledge just made good money in three marijuana stocks, while others with less knowledge lost money in two marijuana stocks and missed the opportunity to buy the third. To make money in marijuana stocks, investors need to understand
Money is to be made in marijuana stocks in the long run. But the recent buzz may be overdone. Canada’s Tilray TLRY, has become the first cannabis company to conduct a U.S. IPO. The shares were priced at $17 per share, higher than expectations due to oversubscription. The stock soared
Mom-and-pop investors have become excited about the use of marijuana and cannabis. They have been aggressively pouring their savings into marijuana stocks with stars in their eyes about how rich they are about to become. Unfortunately, those investors have not had the proper guidance or expertise about when and how
Fortunes may be made in legal cannabis over the coming years. As a result, bullish sentiment is building on cannabis stocks both for recreational and medicinal uses. Adding to the bullish sentiment is the first-ever cannabis-based medicine to get a favorable recommendation from an advisory panel to the U.S. Food